Kelowna, BC – September 30, 2026 -- Doseology Sciences Inc. (CSE: MOOD, OTCQB: DOSEF, FSE: VU70) has appointed Kareem Baalbaki as interim CEO, interim CFO and director, alongside Jeremy Wright as a new board director, replacing outgoing CEO Chris Jackson and CFO Chris Cherry, who have both resigned.
Baalbaki scaled a Canadian CPG operator's revenue fifteenfold before joining Doseology
Baalbaki previously served as Chief Supply Chain Officer at Revive Superfoods, where he helped grow the frozen CPG platform's annual revenue from approximately $10 million to $150 million. The Toronto-based executive holds more than a decade of operations and supply-chain experience, including restructuring underperforming businesses and advising boards on governance and organizational design. He holds a Master of Science in International Business from the University of Lincoln in the United Kingdom.
New director Jeremy Wright brings dual TSX and Nasdaq public-company finance credentials
Wright currently serves as CFO of TSX-listed Avant Brands Inc., a role he returned to in 2024 after founding the company's finance function as GTEC Holdings from 2017 to 2019, when he helped raise more than $45 million ahead of its 2021 TSX uplisting. Avant has been named to The Globe and Mail's Top Growing Companies list for three consecutive years, 2023 through 2025. Between 2020 and 2022, Wright served as CFO of Alpha Cognition Inc., raising more than $20 million during its qualifying transaction; Alpha Cognition later uplisted to Nasdaq under ticker ACOG and became a commercial-stage biopharmaceutical company following FDA approval of its lead drug, ZUNVEYL. A former Senior Manager at Deloitte LLP Canada, Wright holds a B.A. (Hons.) in Environmental Economics from Brock University.
Doseology settles $13,548.39 in consulting compensation through a share issuance
Separate from the leadership changes, Doseology issued 75,268 common shares at a deemed price of $0.18 per share to settle $13,548.39 in accrued share-based consulting compensation owed to a former consultant, following its September 23, 2026 disclosure. The settlement shares carry resale restrictions under Canadian securities law.